Global Viral Inactivation Market

The global Viral Inactivationmarket was valued at USD 320.34million in 2016 and is projected to reach USD 903.43millionby 2025, growing at a CAGR of 12.21% from 2017 to 2025.
This method is one in which the viruses may remain in the final product, but in a non-infective form. The method is highly applicable in modern vaccine development techniques and treatment of other viral diseases involving their study and research. The market is thus expected to grow at a high CAGR.

Sample Infographics:



Market Dynamics:
1. Market Drivers
1.1 Rapid Growth in R&D sector and discoveries
1.2 Increasing fund availability for Biopharmaceutical sector
1.3 Increasing demand for Biopharmaceuticals
1.4 Increasing support from public and private sector
1.5 High Incidence and Large Economic Burden of Chronic Diseases
2. Market Restraints
2.1 High Degree of Consolidation to Act as A Major Barrier for New Entrants

Market Segmentation:
1. By Application:
1.1 Vaccines and Therapeutics
1.2 Blood and Blood Products
1.3 Cellular and Gene Therapy Products
1.4 Tissues and Tissue Products
1.5 Stem Cell Products

2. By End User:
2.1 Pharmaceutical and Biotechnology Companies
2.2 Contract Research Organizations
2.3 Academic Research Institutes
2.4 Other End Users

3. By Product:
3.1 Kits and Reagents
3.2 Services
3.3 Viral Inactivation Systems and Accessories

4. By Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa

Competitive Landscape:
The major players in the market are as follows:
1. Danaher Corporation
2. Merck KGAA
3. Parker Hannifin Corporation
4. Sartorius AG
5. SGS SA
6. Charles River Laboratories International, Inc.
7. Clean Cells Inc.
8. Rad Source Technologies, Inc.
9. Texcell, Inc.
10. Viral Inactivated Plasma Systems SA
11. Wuxi Pharmatech (Cayman) Inc.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

RESEARCH METHODOLOGY:
Research study on the Viral Inactivationmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team.

1 INTRODUCTION OF GLOBAL VIRAL INACTIVATION MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VIRAL INACTIVATIONMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL VIRAL INACTIVATION MARKET,BY APPLICATION
5.1 Vaccines and Therapeutics
5.2 Blood and Blood Products
5.3 Cellular and Gene Therapy Products
5.4 Tissues and Tissue Products
5.5 Stem Cell Products

6 GLOBAL VIRAL INACTIVATION MARKET, BY END USER
6.1 Pharmaceutical and Biotechnology Companies
6.2 Contract Research Organizations
6.3 Academic Research Institutes
6.4 Other End Users

7 GLOBAL VIRAL INACTIVATION MARKET, BY PRODUCT
7.1 Kits and Reagents
7.2 Services
7.3 Viral Inactivation Systems and Accessories

8 GLOBAL VIRAL INACTIVATIONMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 – 2025

9 GLOBAL VIRAL INACTIVATIONMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Danaher Corporation
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck KGAA
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Parker Hannifin Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Sartorius AG
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 SGS SA
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Charles River Laboratories International, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Clean Cells Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Rad Source Technologies, Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Texcell, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 Viral Inactivated Plasma Systems SA
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

10.11 Wuxi Pharmatech (Cayman) Inc.
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Development

11 Appendix
11.1 Related Reports